Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis

Back to Search
Print
Bookmark Trial

NCT00440492

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Los Angeles, California, 90048, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Arthritis, Rheumatoid
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Men or women of nonchildbearing potential with rheumatoid arthritis (RA), aged 18 to 75 years

- RA disease onset after 16 years of age and has had the disease for at least 6 months

- Must be receiving a stable, well-tolerated oral dose of methotrexate (5 to 25 mg) taken once weekly for at least 3 months

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Evidence of unstable clinically significant disease

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Arthritis, RheumatoidStudy of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate
NCT00628095
  1. Mesa, Arizona
  2. Debary, Florida
  3. Lake Mary, Florida
  4. Tampa, Florida
  5. Avon, Indiana
  6. New Orleans, Louisiana
  7. Frederick, Maryland
  8. Columbia, Missouri
  9. Columbia, Missouri
  10. Reno, Nevada
  11. Cincinnati, Ohio
  12. Spokane, Washington
  13. Providencia, Santiago, RM
  14. Ceska Lipa,
  15. Praha 2,
  16. Praha 4,
  17. Incheon,
  18. Pusan,
  19. Mexico, D.f.
  20. Krakow,
  21. Poznan,
  22. Poznan,
  23. Santiago de Compostela, A Coruña
  24. A Coruña,
  25. Madrid,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Arthritis, RheumatoidEtanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan)
NCT01230177
  1. Sendai, Miyagi
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Arthritis, RheumatoidStudy To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis
NCT00440492
  1. Los Angeles, California
  2. Palo Alto, California
  3. Lake Success, New York
  4. Rochester, New York
  5. Charlotte, North Carolina
  6. Columbus, Ohio
  7. Vancouver, British Columbia
  8. Mississauga, Ontario
  9. Montreal, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Arthritis, RheumatoidDose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis
NCT00550355
  1. Peoria, Arizona
  2. Daytona Beach, Florida
  3. Port Orange, Florida
  4. Overland Park, Kansas
  5. Overland Park, Kansas
  6. Frederick, Maryland
  7. Lansing, Michigan
  8. Duncansville, Pennsylvania
  9. Dallas, Texas
  10. Buenos Aires,
  11. Pleven,
  12. Sofia,
  13. Sofia,
  14. Brno,
  15. Praha 4,
  16. Mexico, D.f.
  17. Mexico, DF
  18. Bialystok,
  19. Bialystok,
  20. Krakow,
  21. Krakow,
  22. Warszawa,
  23. Wroclaw,
  24. Piestany,
  25. Santiago de Compostela, A Coruña
ALL GENDERS
21 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis
Official Title  ICMJE An Open-Label Study To Evaluate The Potential Pharmacokinetic Interaction Between PLA-695 And Methotrexate When Coadministered Orally To Adult Subjects With Rheumatoid Arthritis
Brief Summary The purpose of this study is to determine if PLA-695 changes the blood concentrations of methotrexate when administered together.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Arthritis, Rheumatoid
Intervention  ICMJE Drug: PLA-695
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE Not Provided
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE November 2007
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Men or women of nonchildbearing potential with rheumatoid arthritis (RA), aged 18 to 75 years
  • RA disease onset after 16 years of age and has had the disease for at least 6 months
  • Must be receiving a stable, well-tolerated oral dose of methotrexate (5 to 25 mg) taken once weekly for at least 3 months

Exclusion Criteria:

  • Evidence of unstable clinically significant disease
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00440492
Other Study ID Numbers  ICMJE 3175A3-104
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP